At present there is no consensus on the treatment of classical Hodgkin's lymphoma (CHL) following relapse. The aim of the present study was to access the class I-selective histone deacetylase (HDAC) inhibitor (HDACI) MGCD0103 on the expression levels of Bcl-2, nuclear factor (NF)-kappa B and programmed death-ligand 1 (PD-L1) in CHL, to explore the possible therapeutic value of MGCD0103 in combined relative target drugs for patients with CHL. In L1236 and L428 cell lines, apoptosis and cell cycle stage were identified using flow cytometry, and the effects of HDACI on CHL were assessed in terms of Bcl-2, NF-kappa B and PD-L1 expression levels, which were detected by western blotting and co-focusing experiments. The results demonstrated that MGCD0103 could induce cell apoptosis and cell cycle arrest, down-regulate Bcl-2 and increase NF-kappa B and PD-L1 expression levels in L1236 and L428 cell lines. MGCD0103 decreases Bcl-2 levels and upregulates PD-L1, which indicates that the combined use of HDACIs and a PD-L1 inhibitor in theory may improve treatment outcomes in patients with CHL. MGCD0103 may also up-regulate NF-kappa B, which seems to induce resistance towards anti-apoptotic drugs. Clinical trials combining HDACIs with NF-kappa B and/or PD-L1 inhibitors should be designed to further improve treatment outcomes for patients with CHL.
[1]Fudan Univ, Pudong Med Ctr, Shanghai Pudong Hosp, Dept Gastrointestinal Surg, Shanghai 201399, Peoples R China;
[2]Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, 270 Dongan Rd, Shanghai 200031, Peoples R China;
[3]Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Lymphoma, 789 Suzhou Rd, Urumqi 830011, Xinjiang, Peoples R China
(8.0+极速模式)